<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>27. Monoclonal Antibodies - Production, Uses or Applications</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-26-autoimmunity.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 69.23%;"></div> <!-- Placeholder value, update if this is not #27 -->
                        </div>
                       <span class="progress-text">Lecture 27 of 39</span> <!-- Update text -->
                    </div>
                    <a href="#" class="nav-button disabled"> <!-- Last chunk -->
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Monoclonal antibodies</h1>
                <p>Dr Oyaro</p>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: section-learning-objectives -->
                <section id="section-learning-objectives" class="content-section" aria-labelledby="section-heading-learning-objectives">
                    <h2 id="section-heading-learning-objectives" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Learning objectives</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Definitions involved</li>
                            <li>Process of purification/isolation</li>
                            <li>Uses and applications</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_15c45b43aa1b408c9888g-03-1.jpg" alt="Diagram of an antibody molecule showing Fab (Fragment, antigen binding) and Fc (Fragment, crystalline) regions. The Fab region contains variable domains for antigen binding, and the Fc region contains constant domains that determine effector functions." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: section-learning-objectives -->

                <!-- START: section-definitions -->
                <section id="section-definitions" class="content-section" aria-labelledby="section-heading-definitions">
                    <h2 id="section-heading-definitions" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Definitions</span>
                    </h2>
                    <div class="content-card">
                        <p>Fab = Fragment, antigen binding<br>
                        Fc = Fragment, crystalline</p>
                        <p>The Fc fragment specifies other biological activities of the molecule. For example, the Fc fragment may determine whether the antibody simply prevents signaling through a receptor, or alternatively, causes the cell's destruction through complement fixation or targeting immune effector cells.</p>
                        <h3 class="subsection-heading">Monoclonal antibodies (mAb or moAb)</h3>
                        <p>Monoclonal antibodies are:</p>
                        <ul>
                            <li>monospecific antibodies that are identical because they are produced by one type of immune cell (a single parent cell).</li>
                            <li>Antibodies produced from a single clone of B cells.</li>
                            <li>Produced by fusing a B cell secreting the desired antibody with a myeloma cell capable of growing indefinitely in tissue culture.</li>
                        </ul>
                        <p>Monoclonal antibodies all have identical antigen-binding sites. i.e. they all bind to the same epitope with the same affinity.</p>
                        <ul>
                            <li>They are all of the same antibody class (isotype).</li>
                        </ul>
                        <h3 class="subsection-heading">Polyclonal antibodies</h3>
                        <ul>
                            <li>are a mixture of antibodies with different antigen binding sites that may bind to different epitopes or antigens with varying affinities.</li>
                            <li>They may be of different antibody classes.</li>
                            <li>The serum obtained from an immunized animal is referred to as a polyclonal antiserum.</li>
                        </ul>
                        <h3 class="subsection-heading">Hybridoma</h3>
                        <ul>
                            <li>are cells that have been engineered to produce a desired antibody in large amounts.</li>
                            <li>To produce monoclonal antibodies, B-cells are removed from the spleen of an animal that has been challenged with the relevant antigen</li>
                            <li>These B-cells are then fused with myeloma tumor cells that can grow indefinitely in culture</li>
                            <li>This fusion is performed by making the cell membranes more permeable.</li>
                            <li>The fused hybrid cells (hybridomas), being cancer cells, will multiply rapidly and indefinitely and will produce large amounts of the desired antibodies</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-definitions -->

                <!-- START: section-mab-production-steps -->
                <section id="section-mab-production-steps" class="content-section" aria-labelledby="section-heading-mab-production-steps">
                    <h2 id="section-heading-mab-production-steps" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Practical steps in monoclonal antibody production:</span>
                    </h2>
                    <div class="content-card">
                        <ol>
                            <li>Immunize animal</li>
                            <li>Isolate spleen cells (containing antibody-producing B cells)</li>
                            <li>Fuse spleen cells with myeloma cells (e.g. using PEG - polyethylene glycol)</li>
                            <li>Allow unfused B cells to die</li>
                            <li>Add aminopterin to culture to kill unfused myeloma cells</li>
                            <li>Clone remaining cells (place 1 cell/well and allow each cell to grow into a clone of cells)</li>
                            <li>Screen supernatant of each clone for presence of the desired antibody.</li>
                            <li>Grow the chosen clone of cells in tissue culture indefinitely.</li>
                            <li>Harvest antibody from the culture supernatant.</li>
                        </ol>
                        <figure>
                            <img src="../assets/images/2025_06_15_15c45b43aa1b408c9888g-09-1.jpg" alt="Diagram illustrating the hybridoma technique for monoclonal antibody production: 1. Immunize mouse. 2. Isolate antibody-forming cells from spleen. 3. Fuse with myeloma cells. 4. Select hybridomas in HAT medium. 5. Clone positive hybridomas. 6. Expand clones and harvest monoclonal antibodies." class="content-image">
                            <figcaption>Monoclonal Antibody Production</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: section-mab-production-steps -->

                <!-- START: section-hybridoma-selection -->
                <section id="section-hybridoma-selection" class="content-section" aria-labelledby="section-heading-hybridoma-selection">
                    <h2 id="section-heading-hybridoma-selection" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Hybridoma Selection "The HAT Trick"</span>
                    </h2>
                    <div class="content-card">
                        <p>Myeloma cells lack certain enzymes so that they can not use hypoxanthine, aminopterin, and thymidine (HAT medium) as a source for nucleic acid biosynthesis and will die in culture.</p>
                        <p>Only B cells that have fused with the engineered myeloma cells will survive in culture when grown in HAT medium.</p>
                    </div>
                </section>
                <!-- END: section-hybridoma-selection -->

                <!-- START: section-purification-mabs -->
                <section id="section-purification-mabs" class="content-section" aria-labelledby="section-heading-purification-mabs">
                    <h2 id="section-heading-purification-mabs" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Purification of monoclonal Antibodies</span>
                    </h2>
                    <div class="content-card">
                        <p>Contaminants:</p>
                        <ul>
                            <li>Media components: hormones, growth factors, transferrins......etc</li>
                            <li>Viral, bacterial, endotoxins...etc</li>
                        </ul>
                        <p>Methods of purification:</p>
                        <ol>
                            <li>Filtration for larger particles</li>
                            <li>Ultrafiltration esp. for low concentration samples</li>
                            <li>Chromatography:
                                <ul>
                                    <li>Ion exchange chromatography (either cation or anion) can be used (Most impurities are usually anions)</li>
                                    <li>Size exclusion chromatography</li>
                                </ul>
                            </li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-purification-mabs -->

                <!-- START: section-recombinant-mabs -->
                <section id="section-recombinant-mabs" class="content-section" aria-labelledby="section-heading-recombinant-mabs">
                    <h2 id="section-heading-recombinant-mabs" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Recombinant monoclonal antibodies</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>The term recombinant and especially recombinant DNA refers to an artificial method of producing DNA (synthetic DNA and proteins).</li>
                            <li>Recombinant DNA is produced through the addition of relevant DNA into an existing organismal genome, such as the plasmid of bacteria</li>
                            <li>Recombinant antibody engineering involves the use of viruses or yeast to create antibodies, rather than mice.</li>
                            <li>A segment of DNA is recombined (recombinant) with the original DNA of the bacteria, these genetically modified bacteria rapidly reproduce and by that reproduce the DNA segment that was recombined with the original genome.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-recombinant-mabs -->

                <!-- START: section-uses-mabs -->
                <section id="section-uses-mabs" class="content-section" aria-labelledby="section-heading-uses-mabs">
                    <h2 id="section-heading-uses-mabs" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Uses of monoclonal Abs</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Measuring protein and drug levels in serum</li>
                            <li>Typing tissue and blood</li>
                            <li>Identifying infectious agents</li>
                            <li>Identifying clusters of differentiation (CDs) for classification and follow-up therapy of leukemias and lymphomas</li>
                            <li>Identifying tumor metastasis</li>
                            <li>Identifying and quantifying hormones</li>
                            <li>Immunoaffinity Purification</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-uses-mabs -->

                <!-- START: section-applications-mabs -->
                <section id="section-applications-mabs" class="content-section" aria-labelledby="section-heading-applications-mabs">
                    <h2 id="section-heading-applications-mabs" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Applications of Monoclonal Antibodies</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li><strong>Diagnostic Applications</strong></li>
                            <li><strong>Therapeutic Applications</strong>
                                <ul>
                                    <li>Transplant rejection</li>
                                    <li>Cardiovascular disease</li>
                                    <li>Cancer</li>
                                    <li>Infectious Diseases</li>
                                    <li>Inflammatory disease</li>
                                </ul>
                            </li>
                            <li><strong>Clinical Applications</strong>
                                <ul>
                                    <li>Purification of drugs, Imaging the target</li>
                                </ul>
                            </li>
                            <li><strong>Future Applications</strong>
                                <ul><li>Fight against Bioterrorism</li></ul>
                            </li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-applications-mabs -->

                <!-- START: section-diagnostic-applications -->
                <section id="section-diagnostic-applications" class="content-section" aria-labelledby="section-heading-diagnostic-applications">
                    <h2 id="section-heading-diagnostic-applications" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Diagnostic Applications (Immuno-histochemistry)</span>
                    </h2>
                    <div class="content-card">
                        <ol>
                            <li>Tissues and tumors can be classified based on their expression of certain defined markers: e.g. Prostate specific antigen(PSA)</li>
                            <li>Classification of tissues and tumors</li>
                            <li>Distinguishing morphologically similar lesions, like mesothelioma and adenocarcinoma</li>
                            <li>Detecting small quantities of metastatic cancer and MDR</li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-diagnostic-applications -->

                <!-- START: section-therapeutic-applications -->
                <section id="section-therapeutic-applications" class="content-section" aria-labelledby="section-heading-therapeutic-applications">
                    <h2 id="section-heading-therapeutic-applications" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Therapeutic Applications</span>
                    </h2>
                    <div class="content-card">
                        <p>One possible treatment for cancer involves monoclonal antibodies that bind only to cancer cell-specific antigens and induce an immunological response against cancer cells.<br>
                        Three mechanisms responsible for the cancer treatment:</p>
                        <ol>
                            <li>mAbs act directely when binding to a cancer specific antigens and induce immunological response to cancer cells(apoptosis, inhibiting growth)</li>
                            <li>mAbs can be modified for delivery of a toxin, radioisotope, cytokine or other active conjugates.</li>
                            <li>it is also possible to design bispecific antibodies that can bind with their Fab regions both to target antigen and to an effector cell</li>
                        </ol>
                    </div>
                </section>
                <!-- END: section-therapeutic-applications -->

                <!-- START: section-naked-mabs -->
                <section id="section-naked-mabs" class="content-section" aria-labelledby="section-heading-naked-mabs">
                    <h2 id="section-heading-naked-mabs" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">'Naked' Monoclonal Antibodies</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>'Naked' means these antibodies are not fused to a toxin</li>
                            <li>Naked Monoclonal antibodies can kill cells via a variety of mechanisms, including: Antibody-Dependent Cellular Cytotoxicity (ADCC), Complement-Dependent Cytotoxicity (CDC), and direct induction of apoptosis</li>
                            <li>However, the precise clinical mechanisms often remain uncertain</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-naked-mabs -->

                <!-- START: section-antibody-structure-recap -->
                <section id="section-antibody-structure-recap" class="content-section" aria-labelledby="section-heading-antibody-structure-recap">
                    <h2 id="section-heading-antibody-structure-recap" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">The structure of antibodies</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_15_15c45b43aa1b408c9888g-18-1.jpg" alt="Diagram of an antibody molecule showing heavy and light chains, variable and constant regions, antigen binding sites (Fab), and the Fc region. Disulfide bonds are also indicated." class="content-image">
                            <figcaption>The antibody molecule</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: section-antibody-structure-recap -->

                <!-- START: section-evolution-therapeutic-antibodies -->
                <section id="section-evolution-therapeutic-antibodies" class="content-section" aria-labelledby="section-heading-evolution-therapeutic-antibodies">
                    <h2 id="section-heading-evolution-therapeutic-antibodies" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Evolution of Therapeutic Antibodies</span>
                    </h2>
                    <div class="content-card">
                        <figure>
                            <img src="../assets/images/2025_06_15_15c45b43aa1b408c9888g-19-1.jpg" alt="Diagram illustrating the evolution of therapeutic antibodies from fully murine (-omab), to chimeric (-ximab with mouse variable regions and human constant regions), to humanized (-zumab with mouse CDRs and human framework/constant regions), to fully human (-umab)." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: section-evolution-therapeutic-antibodies -->

                <!-- START: section-nomenclature-therapeutic-antibodies -->
                <section id="section-nomenclature-therapeutic-antibodies" class="content-section" aria-labelledby="section-heading-nomenclature-therapeutic-antibodies">
                    <h2 id="section-heading-nomenclature-therapeutic-antibodies" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Nomenclature of Therapeutic Antibodies</span>
                    </h2>
                    <div class="content-card">
                        <p>Terminate the name in -ximab for chimeric antibodies and -umab for humanized antibodies.</p>
                        <!-- Note: This is a simplification. -umab is for fully human. -zumab is for humanized. -->
                    </div>
                </section>
                <!-- END: section-nomenclature-therapeutic-antibodies -->

                <!-- START: section-rituximab -->
                <section id="section-rituximab" class="content-section" aria-labelledby="section-heading-rituximab">
                    <h2 id="section-heading-rituximab" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Rituximab (Rituxan)</span>
                    </h2>
                    <div class="content-card">
                        <p>Rituximab is a chimeric monoclonal antibody that targets the CD20 B-cell antigen.<br>
                        This antigen is expressed on 90% of B-cell neoplasms.<br>
                        The precise biological functions of CD20 are uncertain, but the antibody is believed to function by flagging the B-cells for destruction by the body's own immune system, including ADCC, CDC, and apoptosis.<br>
                        This antibody thus leads to the elimination of all B-cells from the body (including cancerous ones), allowing new, healthy B-cells to be produced from lymphoid stem cells.</p>
                    </div>
                </section>
                <!-- END: section-rituximab -->

                <!-- START: section-further-reading -->
                <section id="section-further-reading" class="content-section" aria-labelledby="section-heading-further-reading">
                    <h2 id="section-heading-further-reading" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">More reading on the recommended!</span>
                    </h2>
                    <div class="content-card">
                        <p>Thank you.</p>
                    </div>
                </section>
                <!-- END: section-further-reading -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-26-autoimmunity.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 69.23%;"></div> <!-- Update if this number is different -->
                        </div>
                       <span class="progress-text">Lecture 27 of 39</span> <!-- Update if this number is different -->
                    </div>
                    <a href="#" class="nav-button disabled"> <!-- Last chunk -->
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> 
</body>
</html>